Showing results (151-160 of 237) with videos related to

Sort By:
Pageof 24
Cancer Science|May 31, 2012
A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinomaNobuo Shinohara, Katsuya Nonomura, Takashige Abe, et al.
Cancer Medicine|June 23, 2017
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trialsToru Aoyama, Koji Oba, Michitaka Honda, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2018
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS studyChu Matsuda, Michitaka Honda, Chihiro Tanaka, et al.
Cancer Chemotherapy and Pharmacology|November 4, 2016
Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trialTadamichi Denda, Mitsuro Kanda, Yoshitaka Morita, et al.
Arthritis Research & Therapy|May 30, 2019
Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational studyKazuki M Matsuda, Ayumi Yoshizaki, Ai Kuzumi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Steatotic liver index: An interpretable predictor of steatotic liver disease using machine learning with an enhanced shrinkage methodAkira Okada, Koji Oba, Takeshi Kimura, et al.
Annals of Surgical Oncology|March 28, 2014
Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: the Adjuvant Exercise for General Elective Surgery (AEGES) study groupHaruhiko Cho, Takaki Yoshikawa, Mari S Oba, et al.
Rheumatology (Oxford, England)|February 9, 2022
Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trialSatoshi Ebata, Koji Oba, Kosuke Kashiwabara, et al.
Chemotherapy|February 1, 2013
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot studyHiroshi Nakatsumi, Yoshito Komatsu, Satoshi Yuki, et al.
Molecular Diagnosis & Therapy|January 24, 2014
Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populationsHiromichi Maeda, Shoichi Hazama, Abdiev Shavkat, et al.
Pageof 24